文献速递炎症性肠病

溃疡性结肠炎患者实现内镜与组织学缓解的增量获益:系统评价与Meta分析

Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis.
PubMed 文献 · Gastroenterology · 2020-06-22

本系统评价与Meta分析纳入17项队列研究共2608例临床缓解的溃疡性结肠炎患者,评估更严格缓解定义对复发风险的影响。与Mayo内镜评分1分相比,0分患者临床复发风险降低52%(RR 0.48);在内镜缓解患者中,组织学缓解较持续组织学活动者复发风险降低63%(RR 0.37)。

要点

  • 与MES 1相比,MES 0的UC患者临床复发风险降低52%(RR 0.48)。
  • 内镜缓解患者中,组织学缓解者复发风险较持续活动者降低63%(RR 0.37)。
  • 更严格治疗目标(内镜及组织学缓解)与更低临床复发风险相关。

核心结论

  • 在临床缓解的UC患者中,实现更严格治疗目标(内镜缓解和组织学缓解)者临床复发风险显著低于仅达临床缓解者。

研究设计与样本

  • 系统评价与随机效应Meta分析,纳入17项队列研究共2608例临床缓解的成人UC患者,要求报告至少12个月临床复发风险。

主要发现

  • 与MES 1相比,MES 0患者临床复发风险降低52%(RR 0.48;95%CI 0.37-0.62)。
  • MES 1患者12个月临床复发风险中位数为28.7%;MES 0患者估计年复发风险为13.7%(95%CI 10.6-17.9)。
  • 在内镜缓解(MES 0)患者中,组织学缓解者较持续组织学活动者临床复发风险降低63%(RR 0.37;95%CI 0.24-0.56)。
  • 组织学缓解者估计年临床复发风险为5.0%(95%CI 3.3-7.7)。

关键数值与推荐

  • 临床复发风险比较:MES 0 vs MES 1的RR为0.48(95%CI 0.37-0.62)。
  • 组织学缓解 vs 持续组织学活动的临床复发RR为0.37(95%CI 0.24-0.56)。
  • MES 1患者12个月复发风险中位数28.7%;MES 0患者估计年风险13.7%(95%CI 10.6-17.9)。
  • 组织学缓解者估计年复发风险5.0%(95%CI 3.3-7.7)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Clinical remission, defined by a composite of patient reported outcomes and Mayo endoscopy subscore (MES) 0 or 1 is a recommended treatment target in patients with ulcerative colitis (UC). We estimated whether incorporating more rigorous remission definitions, of endoscopic remission (MES 0) and histologic remission, affects risk of relapse. METHODS: Through a systematic review, we identified cohort studies in adults with UC in clinical remission that reported a minimum 12-month risk of clinical relapse, based on MES (0 vs 1) and/or histologic disease activity, in patients with endoscopic remission. Using random effects meta-analysis, we calculated relative and absolute risk of clinical relapse in patients with UC achieving different treatment targets. RESULTS: In a meta-analysis of 17 studies that included 2608 patients with UC in clinical remission, compared to patients achieving MES 1, patients achieving MES 0 had a 52% lower risk of clinical relapse (relative risk, 0.48; 95% CI, 0.37-0.62). The median 12-month risk of clinical relapse in patients with MES 1 was 28.7%; the estimated annual risk of clinical relapse in patients with MES 0 was 13.7% (95% CI, 10.6-17.9). In a meta-analysis of 10 studies in patients in endoscopic remission (MES 0), patients who achieved histologic remission had a 63% lower risk of clinical relapse vs patients with persistent histologic activity (relative risk, 0.37; 95% CI, 0.24-0.56). Estimated annual risk of clinical relapse in who achieved achieving histologic remission was 5.0% (95% CI, 3.3-7.7). CONCLUSIONS: In a systematic review and meta-analysis of patients with UC in clinical remission, we observed that patients achieving more rigorous treatment endpoints (endoscopic and histologic remission) have a substantially lower risk of clinical relapse compared with patients achieving clinical remission.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Yoon H, Jangi S, Dulai PS, et al. Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterology. 2020. PMID: 32585306. doi:10.1053/j.gastro.2020.06.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。